Andrew A. Hindman, Chief Business Development Officer at ACORDA THERAPEUTICS INC (ACOR), sold 817 shares at $20.54 ($17K) on 2017-12-01, disclosed to the SEC on 2017-12-05.
Scheduled sale ($17k) by Chief Business Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ACOR | SELL | 2018-05-30 | $2.1M | — | Filing → |
| ACOR | SELL | 2017-05-17 | $121K | — | Filing → |
| ACOR | SELL | 2016-12-05 | $9K | — | Filing → |